No abstract available
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / economics
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / economics
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Biomarkers, Tumor / analysis*
-
Breast Neoplasms / chemistry
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / economics
-
Breast Neoplasms / mortality
-
Breast Neoplasms / secondary
-
Cost-Benefit Analysis
-
Disease-Free Survival
-
Drug Costs
-
Female
-
Humans
-
Neoplasm Recurrence, Local*
-
Randomized Controlled Trials as Topic
-
Receptor, ErbB-2 / analysis*
-
Risk Assessment
-
Risk Factors
-
Survival Rate
-
Time Factors
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Biomarkers, Tumor
-
Bevacizumab
-
ERBB2 protein, human
-
Receptor, ErbB-2